drugset
drugset / Trial / NCT00972127

Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen

NCT00972127 ↗

Phase 1 Completed Merz Pharmaceuticals GmbH
CrossoverOpen-labelTreatment

Summary

Primary: * To assess the influence of acidified urinary pH on the renal excretion of Neramexane Secondary: * To assess the influence of acidified urinary pH on the renal excretion of N-OH Neramexane * To assess the steady state plasma pharmacokinetics (PK) of Neramexane and N-OH Neramexane under physiological conditions and under the conditions of urine acidification * To assess safety and tolerability of a repeated dose treatment of Neramexane under physiological conditions and under the conditions of urine acidification

Timeline

Start
2009-10
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Neramexane Small molecule 25 mg —
Subject Neramexane Small molecule 50 mg —

Indications

No indication recorded.